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Background: Reasons underlying the variability of physicians’ preferences for non-selective beta-blockers (BBs) and
endoscopic variceal ligation (EVL) to prevent a first variceal bleed have not been empirically studied. Our aims were
to examine whether 1) gastroenterologists can be classified into distinct subgroups based on how they prioritize
specific treatment attributes and 2) physician characteristics are associated with treatment preference.
Methods: We surveyed physicians to determine their preferred treatment for a standardized patient with large
varices and examined the influence of treatment characteristics on physicians’ decision making using best-worst
scaling. Latent class analysis was used to examine whether physicians could be classified into groups with similar
decision-making styles.
Results: 110 physicians were interviewed (participation rate 39%). The majority spent two or more days a week
performing endoscopies and had practices comprising less than 25% of patients with liver disease. Latent class
analysis demonstrated that physicians could be classified into at least two distinct groups. Most (n = 80, Group 1)
were influenced solely by the ability to visually confirm eradication of varices. In contrast, members of Group 2
(n = 30) were influenced by the side effects and mechanism of action of BBs. Group 1 members were more likely
to have practices that included fewer patients with liver disease and more likely to choose options including EVL
(p = 0.01 for both).
Conclusions: Among physicians, where the majority performs endoscopy on two or more days per week, most
prefer prevention strategies which include EVL. This may be due to the strong appeal of being able to visualize
eradication of varices.
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Gastroesophageal varices are a common complication of
portal hypertension, developing in approximately 50%
of patients with cirrhosis [1]. The risk of bleeding in
patients with moderate to large varices (where moderate
refers to varices elevated above the mucosal surface but
occupying less than one-third of the esophageal lumen
and large occupy more than one-third of the esophageal
lumen) is up to 15% per year and variceal hemorrhage is
associated with a mortality rate of 20% at six weeks [2].
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unless otherwise stated.among patients with cirrhosis, and the high risk of mor-
tality associated with bleeding, screening for varices and
use of prophylactic therapies to prevent a first variceal
hemorrhage are critical components of care.
Two treatment options have been proven to be effect-
ive in preventing first variceal bleed in patients with
cirrhosis and moderate to large gastroesophageal varices:
non-selective beta-blockers (BBs) and endoscopic vari-
ceal ligation (EVL). Meta-analyses show that, compared
to no treatment or placebo, both options reduce the risk
of first variceal hemorrhage and improve survival in
patients with medium/large varices [3]. BBs, have the
added benefit of potentially decreasing other complica-
tions of portal hypertension (such as ascites) [4], but
they have disadvantages including the need for daily
medication and adverse events such as fatigue, dizzinessis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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confirming variceal eradication, but requires conscious
sedation, periodic endoscopic surveillance, and is associ-
ated with a risk of dysphagia and bleeding ulcers. Combin-
ation therapy with both BBs and EVL has not been shown
to improve outcomes [6]. Thus, evidence-based guidelines
recommend that patients with moderate to large gastro-
esophageal varices be treated with either BBs or EVL
(but not both) to prevent an initial hemorrhage [1,4].
Editorials [7,8] and a previous pilot study [9] demon-
strate variability in physician preferences for EVL versus
BBs. The reasons underlying this variability, however,
have not been studied. The objectives of this study were
to examine whether gastroenterologists can be classified
into at least two distinct subgroups based on how they
prioritize the specific attributes related to BBs and EVL
and whether physician characteristics are associated with
group membership and treatment preference.
Methods
Physicians were identified from the American Associ-
ation for the Study of Liver Diseases and American
Gastroenterological Association member directories. For
the latter directory, we included only physicians who
listed themselves under the “liver”, “clinical practice”, or
“esophageal/gastric/duodenal” categories. The resulting
lists were classified by state and duplicates were deleted.
Email addresses were randomized according to a com-
puter generated random list. Physicians were sent an
email containing a link to the online survey, and those
that did not respond after a week were contacted by
telephone. Individuals who agreed to participate after
being telephoned were then sent another email contain-
ing a link to take the survey online. The survey began
with the following question: “Do you care for patients
with cirrhosis?” Only those responding “Yes” were asked
to complete the survey.
We conducted a discrete choice experiment to
evaluate how physicians prioritize information when de-
ciding between non-selective BBs and EVL for primaryFigure 1 Example of a Best-Worst Question.prevention of variceal hemorrhage. Choice format and
analyses used Best-Worst scaling (BWS). BWS is a
choice task which was developed as an alternative to rat-
ing scales in order to obtain respondents’ strength of pref-
erences for a specified set of objects [10]. Surveys using
this approach ask respondents to choose the best and
worst item from a series of sets containing different com-
binations of items from a master list (see example in
Figure 1). BWS has been recently successfully applied to
understand how experts view emerging technologies for
hepatocellular carcinoma [11], elicit patients’ prefer-
ences for colorectal cancer screening [12], examine bar-
riers to integrating personalized medicine into clinical
practice [13], and to develop preference-based quality of
life scales [14].
Before starting the BWS survey, participants were pro-
vided with an example of a BWS question to familiarize
them with the method. The survey examined the impact
of 10 items, which are listed in Figure 2, on physicians’
decision making. An 11th item “none of these factors in-
fluence my decision” was included as a reference cat-
egory and anchoring point. The balanced list of items
(four negative and one positive for each treatment) was
developed by a hepatologist who does not perform en-
doscopy (GGT), a gastroenterologist who does perform
endoscopy (LL), a hepatology research fellow (AS), and
two investigators with expertise in decision making (LF,
JB). For each question, subjects were provided a set of
five items and asked to choose the item which had the
greatest and least impact on their treatment decision. The
experimental design was based on a Youden balanced-
incomplete block design [15,16] consisting of 11 choice
tasks comparing subsets of five of the objects being
examined. Under these experimental conditions, each
object appeared five times, and was presented with each
of the other 10 objects exactly twice. Unlike other ob-
ject scaling approaches like using conjoint analysis with
a 2^K design, Youden designs offer several important
features. First, each choice task has the same number of
objects. Next, each item appears the same number of
Figure 2 Influence of Treatment Characteristics on Physicians’ Decision Making. Legend: Red bars: Group 1 (n = 80) and Blue bars: Group 2 (n = 30).
The scores on the x axis are on a scale from 0–100. Bars to the right of the reference point (=0) represent degree of influence of each attribute.
Bars to the left represent the degree to which respondents were not influenced by specific attributes (i.e. attributes which were discarded as
being unimportant in their decision making).
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factor the same number of times. Finally, as a catalog
design, there are a predetermined number of tasks, and
each person can receive the same version of the survey.
The BWS choice tasks were followed by a series of
questions related to demographic and practice character-
istics. Lastly, we asked respondents to indicate their pre-
ferred choice of treatment for a standardized patient
using the following scenario: “If an upper endoscopy in a
60 year-old man with hepatitis-C cirrhosis (Child-Pugh
class B) and no other relevant medical conditions shows
large esophageal varices, what is your usual choice for
prevention of a first variceal hemorrhage? (Assume the
patient has no strong preference for either option)”.
Mutually exclusive and exhaustive response options
were: 1) Non-selective beta-blockers, 2) Variceal ligation,
3) Both non-selective beta-blockers and variceal ligation,
4) No therapy.
Statistical analyses
For each respondent, utilities (zero-centered values)
were calculated for each level of each attribute using
hierarchical Bayes modeling. This approach has the
advantage in that it can better incorporate heterogeneity
between respondents’ choices [17]. In hierarchical Bayes
modeling, the sample averages (prior information) are
used to update the individual utilities in a number of
iterations until the sample averages stop changing
between iterations. After this convergence, the cycle is
run several thousand more times and the estimates of
each iteration are saved and averaged. We subsequently
performed Latent Class analysis to examine whetherpreferences clustered into at least two segments. Class
solutions were replicated five times from random start-
ing seeds.
We examined associations between physician charac-
teristics [training (gastroenterology fellowship vs. hepatol-
ogy or both), percent of practice devoted to liver disease
(<25% vs. ≥ 25%), number of days performing endoscopy
(≤1.5 vs. ≥ 2 days), practice setting (academic vs. non-
academic), and years in practice (≤20 vs. > 20 years)]
with group membership and treatment choice using
Chi-square tests. The protocol was approved by the Yale
Human Studies Research Program.
Results
Physicians’ characteristics
A total of 391 physicians were sent an email over three
weeks. Of these, 30 email addresses were invalid and 14
physicians were no longer in practice. Of the remaining
347, 68 reported that they did not care for patients with
cirrhosis. Of the 279 physicians who were eligible to par-
ticipate, 28 completed the survey after receiving the email
invitation, and 82 after receiving a phone call. In total, 110
(39%) of eligible physicians completed the survey. Most
were over the age of 50 and an overwhelming majority
was male. Nearly all had completed fellowships in gastro-
enterology or both gastroenterology and hepatology and
most had spent at least 10 years in practice since complet-
ing fellowship. Further details are provided in Table 1.
Physicians’ prioritization of specific treatment attributes
Latent class analysis demonstrated that physicians could be
classified into at least two distinct groups (Log-likelihood
Table 1 Subject characteristics









Hepatology or Liver transplant 1 (1%)
Both 31 (28%)





Days per week dedicated to clinical practice
0 0 (0%)
0.5 (half a day) 3 (3%)
1-3 18 (16%)
>3 89 (81%)





















Work at least 25% of time in a non-fee-for-service
setting (e.g. Kaiser, VA)
Yes 14 (13%)
No 96 (87%)
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members (Group 1) and a smaller group of 30 members
(Group 2). The scores demonstrating how strongly physi-
cians’ decisions were impacted by each attribute by group
membership are provided in Figure 2. Members of the
larger group (Group 1) were influenced primarily by the
ability to visually confirm eradications of varices. In con-
trast, members of Group 2 (n = 30) were influenced primar-
ily by the side effects and mechanism of action of BBs.
Forty percent of physicians with practices including 25% or
more patients with liver disease belonged to Group 2 com-
pared to 18.5% of physicians with practices having less than
25% patients with liver disease (p = 0.01).
Predictors of treatment preference
When presented with the standardized scenario describ-
ing a 60 year old man with hepatitis C cirrhosis and
large esophageal varices, 43% (n = 47) of respondents
chose BBs, 18% (n = 20) chose EVL, and 39% (n = 43)
chose both. Group membership was associated with
treatment choice (Chi-square = 20.9, p = 0.01) (Table 2).
Members of Group 1 (i.e. physicians who were influ-
enced primarily by the ability to visually confirm eradi-
cations of varices) were more likely to prefer treatment
options including EVL (vs. BBs alone) compared to
members of Group 2 (46.2% vs. 20.0%, p = 0.01). We
found no associations between physicians’ demographic,
practice characteristics (including setting), or level of
training, and treatment choice.
Discussion
Both EVL and BBs are effective in the primary prevention
of gastroesophageal variceal bleeding, and guidelines rec-
ommend the use of either of these therapies to prevent
hemorrhage in patients with cirrhosis with medium/large-
sized varices [2,18]. In this study, 39% of the physicians
surveyed chose both BBs and EVL as their preferred
choice for prevention of first variceal hemorrhage for a
60-year-old man with hepatitis C cirrhosis and large
esophageal varices. Thus it appears that combination ther-
apy may be commonly used in clinical practice despite
practice guidelines recommending the use of either, but
not both options, for primary prophylaxis [7,8].
Preference for using both options may be based on
data demonstrating that combined therapy is superior to
either monotherapy for prevention of recurrent bleeding
from esophageal varices [19]. While combination ther-
apy is recommended [19] for the prevention of recur-
rent variceal hemorrhage (where the risk of rebleeding
is in the order of 60% in one year), a more conservative
approach is recommended for primary prophylaxis
(where the risk of hemorrhage is ~15% in one year).
Failure to adhere to guideline recommendations, how-
ever, is well recognized across specialties, and may be
Table 2 Number (%) of physicians preferring each
treatment option according to group membership




Beta-Blocker (%) 27 (33.8) 20 (66.7)
Ligation (%) 16 (20.0) 4 (13.3)
Beta-Blocker + Ligation (%) 37 (46.2) 6 (20.0)
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lines trustworthiness, the perceived relevance of the
guideline recommendations to the individual patient,
and the strength of the evidence underlying each rec-
ommendation [20,21].
The only predictor of treatment preference in this
study was the pattern of influence that specific treatment
characteristics had on physicians’ decision-making. Those
who were influenced primarily by the ability to view eradi-
cation of varices were more likely to prefer a prevention
strategy including EVL compared to those who were influ-
enced primarily by the treatment characteristics related to
BBs. Physician demographic and setting characteristics
were not related to their preferred strategy to prevent first
variceal bleed.
Most of the physicians in this study (the majority of
whom performed endoscopies and had practices with a
small number (<25%) of liver patients) were strongly
influenced by the ability to visualize the effect of treat-
ment (i.e., eradication of the varices). This observation
is consistent with studies demonstrating that physical
explanations are significantly more persuasive than less
tangible mechanisms of action [22,23]. In contrast, mem-
bers of the smaller group (Group 2) (60% of whom had
practices comprising more than 25% of liver patients)
focused primarily on the mechanism of action and side
effects of BBs and were more likely to choose BBs alone
for primary prophylaxis. Thus the results suggest that
members of Group 2 weighed the risk of side effects in
their decision making, but preferred the risk-benefit
profile of these medications over that of EVL.
The strengths of this study lie in the study design and
methods used to evaluate preferences. BWS is a well-
validated method of evaluating the influence of specific
attributes. Due to an increased awareness of this method
in medicine [24,25], this approach has increased in
popularity as a measure to inform medical decision mak-
ing in recent years [12,26,27]. BWS better discriminates
between items and between segments of the study popu-
lation than rating scales; thus, producing more accurate
estimates of individual as well as group-level preferences
[24,25]. Moreover, scale-related response bias is not a
concern with BWS, because respondents make choices
instead of indicating their preference using numeric scales.
While BWS has many strengths, one of the criticisms ofthis approach is that it generates priorities on a relative
scale. To address this limitation, we included a specific
item to serve as a reference category in order to be able to
generate scores on an absolute scale.
This study also has certain limitations. While the re-
sponse rate was modest, it is higher than many surveys
involving physicians and the generalizability of our re-
sults is constrained by the characteristics of the respon-
dents. The use of standardized scenarios, while enabling
us to standardize patients’ clinical characteristics, cannot
replicate the complexity of decision making in clinical
practice. Because of the extreme variability in cost across
insurance plans, this factor was not included in the sur-
vey. The relatively small sample size may have limited
our ability to find associations between specific practice
characteristics and preferences. Almost all participants
performed at least some endoscopies, and therefore we
could not effectively evaluate this factor as a predictor of
decision making or treatment preference. We did not
measure access to EVL or physicians’ attitudes towards
the clinical practice guidelines, both which may influ-
ence treatment preferences. Lastly, we cannot provide
data describing non-participants.
Conclusions
In summary, we found that most of the physicians in this
study (the majority of whom performed endoscopies and
had practices with a small number (<25%) of liver pa-
tients) preferred to a strategy including EVL to prevent
first variceal bleed in patients with cirrhosis. This may be
due to the strong appeal of being able to visualize eradica-
tion of varices. Further research is needed to better under-
stand and confirm this practice pattern and to develop
interventions to improve adherence to guidelines.
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